GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice

$389,162
Joseph C. Glorioso · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA

Double-Strand Break Sensing, Signaling, and Repair

$389,097
John A Tainer · University Of Calif-Lawrenc Berkeley Lab · P01 · FY2013 · CA

Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers

$389,092
Geoffrey I Shapiro · Dana-Farber Cancer Inst · R01 · FY2023 · CA

(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy

$389,055
Elad Ziv · University Of California, San Francisco · R01 · FY2020 · CA

MMS22L loss and PARP inhibition in prostate cancer

$388,990
Li Jia · Brigham And Women'S Hospital · R01 · FY2024 · CA

Cell Cycle Checkpoint in Response to DNA Damage

$388,912
Nancy C Walworth · Univ Of Med/Dent Nj-R W Johnson Med Sch · R01 · FY2007 · GM

Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma

$388,908
Cassian Yee · University Of Tx Md Anderson Can Ctr · P50 · FY2021 · CA

Protective role of Clec7a/dectin-1 in CNS autoimmunity

$388,891
Mari L. Shinohara · Duke University · R01 · FY2024 · NS

Novel mechanism of chemokine nitration in bladder cancer

$388,767
Neelam Mukherjee · University Of Texas Hlth Science Center · R01 · FY2025 · CA

Nanoformulated small molecule immunotherapy for SHH medulloblastoma

$388,750
Marina Sokolsky-Papkov · Univ Of North Carolina Chapel Hill · R01 · FY2022 · NS

Nanoformulated small molecule immunotherapy for SHH medulloblastoma

$388,750
Marina Sokolsky-Papkov · Univ Of North Carolina Chapel Hill · R01 · FY2023 · NS

Project 2

$388,732
David A Barbie · Dana-Farber Cancer Inst · P50 · FY2024 · CA

Statistical Methods for Identification and Evaluation of Predictive Biomarkers in Cancer

$388,673
Li Chen · University Of Kentucky · R21 · FY2024 · CA

PPARy, TLR Signaling and Atherosclerosis

$388,601
Christopher K Glass · University Of California, San Diego · P01 · FY2012 · HL

Role of Ly6K in TGF-beta and immune escape pathways of triple negative breast cancer

$388,498
Geeta Upadhyay · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2022 · CA

Core C: Patient Derived Xenograft (PDX)/ Syngeneic Mouse Core

$388,439
Gatien Moriceau · University Of California Los Angeles · P01 · FY2021 · CA

Core C: Patient Derived Xenograft (PDX)/ Syngeneic Mouse Core

$388,439
Gatien Moriceau · University Of California Los Angeles · P01 · FY2020 · CA

Role of type 2 immune response in pancreatic cancer tumorigenesis

$388,432
Prasenjit Dey · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA

Regulation of T cell activation and exhaustion by Tim-3

$388,425
Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · AI

Regulation of T cell activation and exhaustion by Tim-3

$388,425
Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · AI

Regulation of T cell activation and exhaustion by Tim-3

$388,425
Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · AI

Regulation of T cell activation and exhaustion by Tim-3

$388,425
Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · AI

Comprehensive Assessment of Cancer Immunotherapy Response

$388,323
Timothy Perk · Aiq Solutions, Inc. · R43 · FY2020 · CA

Reprogramming myeloid cells to inhibit cancer development

$388,283
Chengcheng Zhang · Ut Southwestern Medical Center · R01 · FY2022 · CA

The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapy

$388,273
Benjamin Izar · Columbia University Health Sciences · R01 · FY2024 · CA